百济-JPM-20240108.pdf

1、A Competitively Advantaged,Next-GenOncology Innovator142nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024Certain statements contained in this presentation and in the accompanying oral presentation,other than statements of fact that are independently verifiable at the date hereof,constitute fo

2、rward-looking statements.Examples of such forward-looking statements include statements regarding the projected size of the oncology market and related sectors;BeiGenes future revenue,profitability and growth;BeiGenes research,discovery,and pre-clinical and early-stage clinical programs and plans;re

3、cent clinical data for BeiGenes product candidates and approvals of its medicines;the conduct of late-stage clinical trials and expected data readouts;additional planned commercial product launches;and the advancement of and anticipated clinical development,regulatory milestones and commercializatio

4、n of BeiGenes medicines and drug candidates.Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors,including BeiGenes ability to demonstrate the efficacy and safety of its drug candidates;the clinical results for its drug

5、candidates,which may not support further development or marketing approval;actions of regulatory agencies,which may affect the initiation,timing and progress of clinical trials and marketing approval;BeiGenes ability to achieve commercial success for its marketed medicines and drug candidates,if app

6、roved;BeiGenes ability to obtain and maintain protection of intellectual property for its medicines and technology;BeiGenes reliance on third parties to conduct drug development,manufacturing,commercialization and other services;BeiGenes limited experience in obtaining regulatory approvals and comme